Gemfibrozil
- Generic Name
- Gemfibrozil
- Brand Names
- Lopid
- Drug Type
- Small Molecule
- Chemical Formula
- C15H22O3
- CAS Number
- 25812-30-0
- Unique Ingredient Identifier
- Q8X02027X3
- Background
Gemfibrozil is a fibric acid agent, similar to clofibrate, used to treat Type IIb, IV, and V hyperlipidemias. Gemfibrozil is not a first line treatment and is prescribed to patients who have not responded adequately to weight loss, diet, exercise, and other medications.
Gemfibrozil was granted FDA approval on 21 December 1981.
- Indication
Gemfibrozil is indicated to treat patients with Types IV and V hyperlipidemia who have elevated serum triglycerides (usually above 2000mg/dL), elevated VLDL cholesterol, fasting chylomicrons, are at risk of developing pancreatitis, and do not adequately respond to dietary restrictions. Gemfibrozil is also indicated to reduce the risk of developing coronary h...
- Associated Conditions
- Coronary Heart Disease (CHD), Fredrickson classification type IV Hyperlipidemia, Fredrickson classification type V Hyperlipidemia
- Associated Therapies
- -
Study to Assess Drug-Drug Interaction Between Itraconazole or Gemfibrozil and JNJ-56021927
- First Posted Date
- 2014-09-03
- Last Posted Date
- 2016-10-20
- Lead Sponsor
- Aragon Pharmaceuticals, Inc.
- Target Recruit Count
- 45
- Registration Number
- NCT02230033
Modulation of Micro-RNA Pathways by Gemfibrozil in Predementia Alzheimer Disease
- Conditions
- Interventions
- First Posted Date
- 2014-01-24
- Last Posted Date
- 2019-10-08
- Lead Sponsor
- Gregory Jicha, 323-5550
- Target Recruit Count
- 72
- Registration Number
- NCT02045056
- Locations
- 🇺🇸
University of Kentucky, Lexington, Kentucky, United States
Drug-drug Interaction Study With MDV3100 (ASP9785) and Gemfibrozil and Itraconazole
- Conditions
- Interventions
- First Posted Date
- 2013-08-01
- Last Posted Date
- 2013-08-01
- Lead Sponsor
- Astellas Pharma Europe B.V.
- Target Recruit Count
- 41
- Registration Number
- NCT01913379
- Locations
- 🇫🇷
SGS, Paris, France
Initial Screening of Gemfibrozil as a Novel Treatment for Tobacco Addiction
- First Posted Date
- 2013-06-13
- Last Posted Date
- 2017-04-20
- Lead Sponsor
- Centre for Addiction and Mental Health
- Target Recruit Count
- 28
- Registration Number
- NCT01876810
- Locations
- 🇨🇦
Centre of Addiction and Mental Health, Toronto, Ontario, Canada
🇨🇦Centre for Addiction and Mental Health, Toronto, Ontario, Canada
The Effect of Gemfibrozil, Ketoconazole and Clarithromycin on the Amount of LY2409021 in the Bloodstream
- Conditions
- Interventions
- First Posted Date
- 2013-04-19
- Last Posted Date
- 2019-03-08
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 30
- Registration Number
- NCT01836198
- Locations
- 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Evansville, Indiana, United States
A Study to Assess the Effect of Multiple Doses of Gemfribozil on a Single Dose of ASP3652, and to Assess the Effects of Multiple Doses of ASP3652 on a Single Dose of Repaglinide in the Body of Healthy Subjects
- Conditions
- Interventions
- First Posted Date
- 2013-02-22
- Last Posted Date
- 2013-02-22
- Lead Sponsor
- Astellas Pharma Europe B.V.
- Target Recruit Count
- 48
- Registration Number
- NCT01797198
- Locations
- 🇬🇧
PAREXEL Early Phase Clinical Unit, Harrow, United Kingdom
A Study of Evacetrapib in Healthy Participants
- First Posted Date
- 2012-11-29
- Last Posted Date
- 2018-10-03
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 24
- Registration Number
- NCT01736254
- Locations
- 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Daytona Beach, Florida, United States
Study to Assess the Pharmacokinetics of GSK1278863A Coadministered With a High Fat Meal or an Inhibitor of CYP2C8 (Gemfibrozil)
- Conditions
- Interventions
- First Posted Date
- 2011-06-20
- Last Posted Date
- 2017-06-09
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 23
- Registration Number
- NCT01376232
- Locations
- 🇮🇳
GSK Investigational Site, Electronics City, Bengalore, India
A Pharmacokinetics Study of the Effects of GSK2118436 on Warfarin, the Effects of Ketoconazole and Gemfibrozil on GSK2118436, and the Effects of Repeat Doses of GSK2118436 in Subjects With BRAF Mutant Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2011-04-25
- Last Posted Date
- 2017-11-13
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 48
- Registration Number
- NCT01340846
- Locations
- 🇬🇧
GSK Investigational Site, London, United Kingdom
Relative Bioavailability of Single Dose Empagliflozin (BI 10773) When Co-administered With Multiple Doses of 600 mg Gemfibrozil Compared to Single Dose Treatment With Empagliflozin (BI 10773) When Given Alone in Healthy Volunteers
- First Posted Date
- 2011-02-23
- Last Posted Date
- 2014-06-18
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 18
- Registration Number
- NCT01301742
- Locations
- 🇩🇪
1245.58.1 Boehringer Ingelheim Investigational Site, Biberach, Germany
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.